Vaxcyte reports positive VAX-24 Phase 1/2 data; Q3 net loss $57.9M, cash $366.2M plus $650.7M offering

Vaxcyte, Inc.

2022-Q3 EPS reported -$2.42

Q3 net loss $57.9M (vs $26.6M YoY); R&D $47.7M (up from $20.4M) on Phase 3/IND activities.
Cash $366.2M at Sep 30, plus ~$650.7M net from Oct follow-on offering.
VAX-24 Phase 1/2 met endpoints; at 2.2mcg dose, non-inferiority for all 20 PCV20 serotypes, 16 higher, 4 superior.
Expect VAX-24 Phase 2 data in 65+ in H1 2023; infant IND in H1 2023; VAX-XP IND in H2 2023.
Appointed Mark Wiggins as CBO and Jakub Simon as CMO.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Vaxcyte, Inc. reported financial results for third quarter ended September 30, 2022.

Period: third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 7, 2022, Vaxcyte, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

Vaxcyte, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-022628

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.